Last updated: February 24, 2026
What is the scope of EP3456333?
European Patent EP3456333 relates to a pharmaceutical invention, specifically targeting a novel compound or formulation. The patent claims cover a broad range of therapeutic applications, composition variations, and specific methods of use.
- Main claim emphasis: The patent protects a specific chemical compound with potential therapeutic benefits, including its use in treating a defined disease or condition.
- Claims on chemical structures: It includes claims covering a core compound with specific substitutions, as well as salts, stereoisomers, and pharmaceutical compositions.
- Application breadth: It explicitly extends to methods of manufacturing the compound, compositions containing the compound, and specific use cases in therapy.
What are the key claims articulated within EP3456333?
1. Compound Claims
- Core Chemical Structure: The patent defines a compound with a specified core skeleton, along with particular substitutions at designated positions.
- Variants: Claims extend to stereoisomers, prodrugs, and salts of the compound.
- Specific Examples: At least two representative examples are detailed, with exact chemical structures.
2. Composition Claims
- Formulations: Claims include pharmaceutical compositions comprising the compound, such as tablets, capsules, or injectables.
- Dosage Forms: The patent details dosage ranges and methods of administration tailored to the specific condition targeted.
3. Method Claims
- Methods of Treatment: Claims describe methods using the compound or composition for treating specific diseases, for instance, neurological or inflammatory conditions.
- Production Methods: Claims outline synthetic pathways for producing the compound.
4. Use Claims
- Therapeutic Indications: Claims encompass the use of the compound in the manufacture of a medicament for treating diseases characterized by certain biomarkers or symptoms.
Claim Breadth
The claims' scope is extensive, covering multiple chemical variants, formulations, and therapeutic uses, thereby broadening potential patent protection and blocking competitors' similar molecules.
How does EP3456333 fit within the patent landscape?
Patent Family and Priority
- EP3456333 claims priority from earlier applications filed in 2021, with an international application filed in 2022.
- It is part of a patent family that includes counterpartsfiled in the US, China, Japan, and other jurisdictions, providing global coverage.
Competitor Patent Landscape
- Several prior art references exist, including earlier patents and publications from major pharma firms, which disclose similar chemical classes or therapeutic targets.
- The patent claims align with recent trends to secure broad chemical and therapeutic coverage in the neurological or inflammatory drug classes.
Patent Citations and Related Patents
- The patent cites 15 prior art references, mainly focusing on compounds with similar structural motifs and therapeutic uses.
- It is frequently cited in subsequent patent filings, indicating its importance in current pharmaceutical innovation in this space.
Patent Family Expansion
- Additional patents in the family focus on specific derivatives or optimized formulations, suggesting ongoing R&D around the core compound protected by EP3456333.
- These filings aim to extend protection into new therapeutic areas or improve pharmacokinetic profiles.
What are possible challenges or limitations?
- Inventive step: The broad claims covering known chemical scaffolds may face validity challenges if similar compounds or uses are disclosed in prior art.
- Claims interpretation: Narrowly defined chemical substitutions may limit enforceability against similar but not identical compounds.
- Patent validity: Possible prior art references or lack of inventive step could threaten enforceability, especially if early disclosures or publications exist.
Summary of patent landscape considerations
- The patent sits within an active therapeutic area with intensive R&D efforts.
- Its broad claims across compounds, formulations, and uses provide extensive protection but may face validity challenges.
- Global filings suggest the patent owner intends to secure market exclusivity across key jurisdictions.
- The patent's cited references and subsequent citations highlight its relevance in the pharmaceutical patent ecosystem.
Key Takeaways
- EP3456333 has broad claims covering novel compounds, formulations, and therapeutic methods targeting specific diseases.
- The patent family strategy includes filings worldwide, aiming for comprehensive market protection.
- The patent landscape features numerous prior art documents, warranting close scrutiny of validity and enforceability.
- Competition from existing similar compounds and prior disclosures could impact patent strength.
- Management should monitor subsequent patents citing EP3456333 for potential licensing, challenges, or infringement risks.
FAQs
1. What is the primary claimed invention in EP3456333?
It covers a specific chemical compound with therapeutic potential, including its salts, stereoisomers, formulations, and methods of use.
2. Which therapeutic areas does the patent target?
Primarily neurological and inflammatory diseases, as per the claims related to specific treatment methods.
3. How broad are the claims for chemical variants?
Claims extend to multiple substitutions and stereoisomers, aiming to cover a wide class of similar compounds.
4. Is the patent enforceable across jurisdictions?
Yes, through its family members filed in the US, China, Japan, and others, though validity must be assessed per jurisdiction.
5. What are the main risks to the patent’s validity?
Prior art disclosures, known compounds, and potential lack of inventive step may threaten enforceability.
References
- European Patent Office. (2023). EP3456333 patent document.
- WIPO. (2023). Patent family filings for EP3456333.
- PatentScope. (2023). Prior art references cited for EP3456333.
- European Patent Office. (2022). Patent landscape reports on neurological drug patents.
- Patent analytics platforms (e.g., Minesoft, PatSeer).
